Digital Self-Management Program for Medicare Advantage Members With Type 2 Diabetes- Impact on A1c
1 other identifier
interventional
607
1 country
1
Brief Summary
The Digital Self-Management Program for Medicare Advantage Members with Type 2 Diabetes - Impact on A1c trial is a 26-week long, prospective, intent-to-treat, 2-arm randomized controlled trial that aims to evaluate the impact of the Digital Self-Management Program on A1c levels for individuals with uncontrolled Type 2 diabetes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable diabetes-mellitus-type-2
Started Mar 2017
Shorter than P25 for not_applicable diabetes-mellitus-type-2
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 3, 2017
CompletedFirst Submitted
Initial submission to the registry
March 22, 2017
CompletedFirst Posted
Study publicly available on registry
March 28, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 7, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
February 7, 2018
CompletedJune 25, 2019
June 1, 2019
11 months
March 22, 2017
June 23, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Change from Baseline in A1c at 6 months
Change in A1c from study baseline to study end
Baseline and 6 months
Study Arms (2)
Intervention
EXPERIMENTALDiabetes Self-Management Program
Control
NO INTERVENTIONInterventions
The Diabetes Self-Management Program is a platform that includes a smart meter, access to coaching 24/7, and a mobile app and website that help members manage their diabetes. The program offers diabetes education and coaching delivered entirely through the smart meter and mobile app or website.
Eligibility Criteria
You may qualify if:
- Humana Medicare Advantage member
- Type 2 diabetes diagnosis
- HbA1c levels ≥ 8.0% verified by lab test
You may not qualify if:
- Has any of the following conditions: cancer, chronic heart failure, chronic obstructive pulmonary disease, respiratory failure, chronic kidney disease, end stage renal disease, peripheral vascular disease
- Not fluent in English
- Humana membership is part of a Full or Global risk arrangement
- Enrolled in Humana at Home Care Management
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Evidation Healthlead
- Humana Co.Ltd.collaborator
Study Sites (1)
Evidation Health
San Mateo, California, 94401, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jessie Juusola, PhD
Evidation Health
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 22, 2017
First Posted
March 28, 2017
Study Start
March 3, 2017
Primary Completion
February 7, 2018
Study Completion
February 7, 2018
Last Updated
June 25, 2019
Record last verified: 2019-06
Data Sharing
- IPD Sharing
- Will not share